Buquicchio R, Foti C, Loconsole F, Polimeno L, Ventura M T
Dermatological Clinic, Department of Biomedical Science and Human Oncology, University of Bari Medical School, Policlinico, Italy
Department of Interdisciplinary Medicine, Section of Sciences and Technologies of Laboratory Medicine, University of Bari Medical School, Policlinico, Italy
J Biol Regul Homeost Agents. 2017 Jul-Sep;31(3):785-789.
Psoriasis is a chronic inflammatory skin disease with systemic involvement that might predispose to many psoriasis-related comorbidities, such as metabolic syndrome and cardiovascular disorders. Clusterin (Clu), also known as apolipoprotein J (ApoJ), is a highly conserved disulfide-linked heterodimeric glycoprotein implicated in a great variety of physiological and pathophysiological processes including lipid transportation, tissue remodeling, senescence, cell interaction, stress response, inflammation, apoptosis, diabetes mellitus and metabolic syndrome. Serum levels of Clu were assessed in 15 patients with moderate-to-severe psoriasis defined by the presence of a Psoriasis Area and a Severity Index (PASI) value of 10 or more. It was found that the Clu value was significantly higher in patients than in healthy subjects (p <0.001). Our data confirm that the association of psoriatic disease with some comorbidities, especially metabolic and cardiovascular disease, might support the correlation with increased circulating Clu. In particular, it should be pointed out that, according to the recent literature, the Clu could also have a protective role in the comorbidity of psoriasis patients. In addition, it has been published that Clu protects cardiomyocytes against ischemic cell death and is a potential therapeutic agent in the treatment of myocardial infarction; therefore it can be assumed that an artificial enhancement of Clu in the blood could limit the severity of damage also in respect to skin lesions. Although the increase in serum level of Clu was found in all patients with psoriasis, more studies on a larger cohort of patient samples is necessary to confirm the significance of high serum levels of clusterin/ApoJ and to suggest the use of this glycoprotein as an additional new marker in psoriasis pathogenesis. It could be a possibility to improve the prognosis in patients with psoriasis.
银屑病是一种伴有全身受累的慢性炎症性皮肤病，可能易引发许多与银屑病相关的合并症，如代谢综合征和心血管疾病。簇集素（Clu），也称为载脂蛋白J（ApoJ），是一种高度保守的、通过二硫键连接的异二聚体糖蛋白，参与多种生理和病理生理过程，包括脂质运输、组织重塑、衰老、细胞相互作用、应激反应、炎症、细胞凋亡、糖尿病和代谢综合征。对15例中度至重度银屑病患者的血清Clu水平进行了评估，这些患者的银屑病面积和严重程度指数（PASI）值为10或更高。结果发现，患者的Clu值显著高于健康受试者（p<0.001）。我们的数据证实，银屑病与某些合并症，尤其是代谢和心血管疾病的关联，可能支持与循环Clu升高的相关性。特别是，应该指出的是，根据最近的文献，Clu在银屑病患者的合并症中也可能具有保护作用。此外，已发表研究表明Clu可保护心肌细胞免受缺血性细胞死亡，是治疗心肌梗死的潜在治疗剂；因此可以假设，血液中Clu的人工增强也可能限制皮肤病变的损伤严重程度。尽管在所有银屑病患者中均发现血清Clu水平升高，但仍需要对更大样本队列进行更多研究，以证实血清高水平簇集素/ApoJ的意义，并建议将这种糖蛋白用作银屑病发病机制中的另一种新标志物。这有可能改善银屑病患者的预后。
